purposes and are subject to creditor claims in the event of insolvency.
Abbott also holds certain investments as of March 31, 2025 with a carrying value of $
152
million that are accounted for under the equity method of accounting and other equity investments with a carrying value of $
109
million that do not have a readily determinable fair value.
Note 5 — Changes In Accumulated Other Comprehensive Income (Loss)
The changes in accumulated other comprehensive income (loss), net of income taxes, are as follows:
Reclassified amounts for cash flow hedges are recorded as Cost of products sold. Net actuarial losses and prior service cost are included as a component of net periodic benefit costs; see Note 12 — Post-Employment Benefits for additional details.
11
Table of Contents
Abbott Laboratories and Subsidiaries
Notes to the Condensed Consolidated Financial Statements
March 31, 2025
(Unaudited)
Note 6 — Goodwill and Intangible Assets
The total amount of goodwill reported was $
23.4
billion at March 31, 2025 and $
23.1
billion
at December 31, 2024. The amount of goodwill related to reportable segments at March 31, 2025 was $
2.6
billion for the Established Pharmaceutical Products segment, $
285
million for the Nutritional Products segment, $
3.5
billion for the Diagnostic Products segment, and $
16.9
billion for the Medical Devices segment.
F
oreign currency translation adjustments increased goodwill by $
251
million in the first three months of 2025. There were
no
reductions of goodwill relating to impairments in the first three months of 2025.
The gross amount of amortizable intangible assets, primarily product rights and technology, was $
27.3
billion as of March 31, 2025 and $
27.1
billion as of December 31, 2024. Accumulated amortization was $
21.8
billion and $
21.3
billion as of March 31, 2025 and December 31, 2024, respectively. In the first three months of 2025, intangible assets increased
$
34
million due to foreign currency translation. Abbott’s estimated annual amortization expense for intangible assets is approximately $
1.7
billion in 2025, $
1.5
billion in 2026, $
1.2
billion in 2027, $
0.7
billion in 2028 and $
0.6
billion in 2029.
Indefinite-lived intangible assets, which relate to in-process research and development (IPR&D) acquired in a business combination, were $
784
million as of March 31, 2025 and December 31, 2024.
Note 7 — Restructuring Plans
In 2025, Abbott management approved plans to streamline operations in order to reduce costs and improve efficiencies in its diagnostic and medical devices businesses. In the three months ended March 31, 2025, Abbott recorded employee related severance and other charges of $
34
million, of which $
13
million was recorded in Cost of products sold, $
13
million was recorded in Research and development, and $
8
million was recorded in Selling, general and administrative expenses. Payments related to these actions totaled $
4
million in the first three months of 2025 and the remaining